Although CRISPR-based gene therapy for sickle cell disease offers transformative outcomes, drugmakers are striving to develop treatments that are easy to manufacture and can reach much larger numbers of patients.
This is a preview of subscription content, log in via an institution to check access.
Change history
11 April 2024
In the eighth paragraph, the sentence "They do so by disrupting an enhancer bound by the BCL11A erythroid-specific zinc-finger transcription factor, which suppresses γ-globin expression" has been removed from the HTML and PDF versions of the article as it was incorrect.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Innovators want pills to treat sickle cell disease. Can they match gene therapy?. Nat Biotechnol 42, 347–350 (2024). https://doi.org/10.1038/s41587-024-02179-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-024-02179-2
- Springer Nature America, Inc.